The Effectiveness of L-dopa Sources
The aromatic amino acid L-dopa is a nutrient. When combined with carbidopa it becomes the drug Sinemet. Combining L-dopa with benserazide and it becomes the drug Madopar.
Do not listen to the smoke and mirrors out there. Make no mistake. L-dopa is the MOST EFFECTIVE approach to Parkinson’s disease management. Before 1999, if a patient experienced carbidopa side effects or had carbidopa concerns, there was a prescription form containing only L-dopa. Now when there are carbidopa side effects, or concerns relating to the irreversible depletion of vitamin B6, the only preparation available without carbidopa available is the nutrient form.
Carbidopa and benserazide are of no value in addressing or relieving Parkinson’s disease symptoms. They are used to address L-dopa induced nausea. The following is from Lodosyn (carbidopa) prescribing information, “WARNINGS - LODOSYN (Carbidopa) has no antiparkinsonian effect when given alone.” The concern then becomes, “Is the nutritionally sourced L-dopa similar or equal to L-dopa found in the drugs such as Sinemet and Madopar?” Based on controlled studies the United States gatekeeper of medicine, the National Institute of Health (NIH), has taken a formal position on this matter. Based on controlled studies the NIH posted the following:
- “During the LD/CD (L-dopa carbidopa) phase no one discontinued use. For patients who tolerated “nutritionally sourced,” clinical response was similar to L-dopa carbidopa” (Sinemet).
- “A 2017 randomized controlled trial of 18 patients with advanced Parkinson’s disease found that “nutritionally sourced,” at both high and low doses, is as effective and safe as levodopa/benserazide” (Madopar).
Getting rid of carbidopa or benserazide which does not improve Parkinson’s disease symptoms is a big step in the right direction. In removing the potential for carbidopa and benserazide to accelerated vitamin B6 deficiency, there are two other major considerations.
- The 29 potential causes of nutritional deficiency still need to be addressed.
- Self-treatment is not optimal. Many times, patients who self-treat are satisfied with suboptimal results where residual Parkinson’s disease symptoms remain. As time progresses, these symptoms which represent improperly managed nutritional deficiency will collapse and symptoms will return. If medical doctors who suffer Parkinson’s disease are unable to successfully self-treat, what are the chances that a non-medical person will succeed? The answer, none.